Select Page

News Release

Tigermed Center Laboratory Partner Recognized by BARC Global Central Laboratory

September 12, 2018

We are pleased to announce the long-term cooperation between Frontage Lab, Teddy Lab and BARC Global Central Lab, allowing biopharmaceuticalcompanies, Contract Research Organizations and Non-Governmental organizations easy access to both China’s clinical trial data and break-through of technical bottlenecks entering the international market. Today, pharmaceutical companies are not simply checking for the safety of a new drug, but rather expecting special biomarkers to prove the effectiveness of the drug. It’s not easy, but with a wealth of experience and the right support, central laboratories can significantly improve the effectiveness of clinical trials and ensure the safety of patients during the treatment process. In fact, central laboratories are the preferred way to improve the quality of clinical trials and the international multi-center clinical layout.

BARC Global Central Lab, a division of Cerba HealthCare, is a harmonized network of clinical laboratories present on five continents. The vision of the entire Group is to continuously enrich its offerings and services on a full global scale, including China, to enhance its customers’ experience. Partnering with Teddy Lab, BARC adds on an extra solid level to its global footprint, as Teddy Lab, located in Shanghai, China, provides central lab services similar to BARC. Moreover, with the new strong cooperation with Frontage lab, BARC reinforces its expertise in pharmacokinetics & toxicology, which are always a challenge in clinical trials.

Taken together, the strategic partnership between BARC Global Central Lab, Tigermed, Frontage Laboratory and Teddy Laboratory will fully utilize the advantages of both CRO and central laboratories in terms of professional competence, business scale, both domestic (Chinese) and global technical expertise in pharmacokinetic and toxicology.

Recently, Clinical Trials Insight interviewed Mario Papillon, CEO of BARC’s Global Clinical Center Laboratory. Mario Papillon has full confidence in the services of BARC Global Central Laboratory, and this confidence begins with BARC’s global reach. BARC currently has lab branches on five continents and can leverage the support of Cerba’s medical network in Europe’s leading medical biology and diagnostics for better connectivity and rich data. Papillon mentioned, “We can reach more than 1,000 biologists from our employees and partners.” These connections span the medical field worldwide, and Papillon is also proud to mention Frontage Lab and Teddy Lab, both of which are strategic partners of Hangzhou Tigermed Consulting Co., Ltd..


About BARC

For 35 years, BARC Global Central Lab has provided the pharmaceutical and biotech industry with central lab services both in routine and specialized testing within a wide range of fields including oncology, immunology, genetics, microbiology and clinical pathology. BARC’s laboratories routinely conduct medical clinical testing, thus ensuring that the tests offered are also performed on a daily basis for diagnostic purposes, patient stratification, staging and follow-up. With cutting-edge technologies at their disposal, BARC’s medical and scientific experts are specialists in their fields equipped for delivering more than just testing. At BARC, they act as genuine partners for our customers. We encourage that our scientific experts are integrated in our customer’s R&D processes, hence providing a critical advantage in the ever-increasing complex setting of clinical trials.

Contact: Mario PAPILLON phone + email

More information:

LinkedIn®: barc-global-central-laboratory

Twitter®: @BARC_CentralLab


About Tigermed – Teddy Lab – Frontage Lab

Hangzhou Tigermed Consulting Co., Ltd(stock symbol: 300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.

Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 63 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Canada, Korea, Australia, Japan, Malaysia, Singapore, India and Romania with over 3600 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China,owning to our involvement of  over 150 innovative drugs.

Contact: Email:

Teddy Clinical Research Laboratory (Shanghai) Limited. is a joint venture established by Zhejiang Dian Diagnostic Technology Co., Ltd. and Tigermed. It is a central laboratory that establishes quality systems in strict accordance with the requirements of US CAP and ISO15189. It provides rigorous and complex central laboratory solutions for clinical trials of Phase I-IV drugs. The cooperation between Tigermed and Dian Diagnostics aims to create an integrated clinical diagnosis service platform from clinical center laboratory test analysis to patient diagnosis and testing services, to achieve overall optimization of the drug clinical development process, and to establish a domestic central laboratory.


Frontage Laboratories (USA) Co.,Ltd. is a leading supplier of pharmacokinetics and toxicology and was founded in the United States in 2001. Frontage Pharmaceutical Malvern Laboratory is the first laboratory in China to establish FDA-compliant GMP and GLP requirements. It provides international pharmaceutical companies with FDA-compliant scientific research services. The laboratory has passed FDA inspections and received favorable comments. In 2006, Frontage China was put into operation, with branches in Shanghai and Suzhou. In 2014, Tigermed acquired Frontage Laboratories (USA) Co.,Ltd. and expanded the upstream industrial chain of Tigermed. In March 2018,Frontage Laboratories (USA) Co.,Ltd acquired the US CONCORD Biotechnology Company and added pre-clinical based services.

More information: